<?xml version="1.0" ?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" 
 xmlns:mml="http://www.w3.org/1998/Math/MathML">
	<teiHeader>
		<fileDesc xml:id="0"/>
	</teiHeader>
	<text>
		<front/>
		<body/>
		<back>
<listBibl>
	<bibl>. <author>Okubo K, Kurono Y, Ichimura K, Enomoto T, Okamoto Y, Kawauchi H, et al.</author> <title level="a">Japanese guidelines for allergic rhinitis</title> <date>2020</date>. <title level="j">Allergol Int</title> <date>2020</date>;<biblScope unit="volume">69</biblScope>:<biblScope unit="page">331e45</biblScope>.</bibl>
	<bibl>. <author>Matsabura A, Sakashita M, Gotoh M, Kawashima K, Matsuoka B, Kondou S, et al.</author> [<title level="a">National epidemiological survey of nasal allergies</title> <date>2019</date> (<note>Comparison with 1998</note>, <date>2008</date>): <note>breaking news-for otolaryngologists and their families</note>]. <title level="j">Nippon Jibiinkoka Gakkai Kaiho Tokyo</title> <date>2020</date>;<biblScope unit="volume">123</biblScope>:<biblScope unit="page">485e90</biblScope> (<note>in Japanese</note>).</bibl>
	<bibl>. <author>Lamb CE, Ratner PH, Johnson CE, Ambegaonkar AJ, Joshi AV, Day D, et al.</author> <title level="a">Economic impact of workplace productivity losses due to allergic rhinitis compared with select medical conditions in the United States from an employer perspective</title>. <title level="j">Curr Med Res Opin</title> <date>2006</date>;<biblScope unit="volume">22</biblScope>:<biblScope unit="page">1203e10</biblScope>.</bibl>
	<bibl>. <author>Vandenplas O, Vinnikov D, Blanc PD, Agache I, Bachert C, Bewick M, et al.</author> <title level="a">Impact of rhinitis on work productivity: a systematic review</title>. <title level="j">J Allergy Clin Immunol Pract</title> <date>2018</date>;<biblScope unit="volume">6</biblScope>:<biblScope unit="page">1274e86</biblScope>.</bibl>
	<bibl>. <author>Cardell LO, Olsson P, Andersson M, Welin KO, Svensson J, Tennvall GR, et al.</author> <title level="a">TOTALL: high cost of allergic rhinitis-a national Swedish population-based questionnaire study</title>. <title level="j">NPJ Prim Care Respir Med</title> <date>2016</date>;<biblScope unit="volume">26</biblScope>:<biblScope unit="page">15082</biblScope>.</bibl>
	<bibl><author>. Halmai LA, Neilson AR, Kilonzo M</author>. <title level="a">Economic evaluation of interventions for the treatment of asthma in children: a systematic review</title>. <title level="j">Pediatr Allergy Immunol</title> <date>2020</date>;<biblScope unit="volume">31</biblScope>:<biblScope unit="page">150e7</biblScope>.</bibl>
	<bibl>. <author>Ronaldson S, Taylor M, Bech PG, Shenton R, Bufe A</author>. <title level="a">Economic evaluation of SQ-standardized grass allergy immunotherapy tablet (Grazax) in children</title>. <title level="j">Clin-icoecon Outcomes Res</title> <date>2014</date>;<biblScope unit="volume">6</biblScope>:<biblScope unit="page">187e96</biblScope>.</bibl>
	<bibl>. <author>Coons SJ, Rao S, Keininger DL, Hays RD</author>. <title level="a">A comparative review of generic quality-of-life instruments</title>. <title level="j">Pharmacoeconomics</title> <date>2000</date>;<biblScope unit="volume">17</biblScope>:<biblScope unit="page">13e35</biblScope>.</bibl>
	<bibl>. <author>Owen L, Pennigton B, Fischer A, Jeong K</author>. <title level="a">The cost-effectiveness of public health interventions examined by NICE from 2011 to 2016</title>. <title level="j">J Public Health (Oxf)</title> <date>2018</date>;<biblScope unit="volume">40</biblScope>:<biblScope unit="page">557e66</biblScope>.</bibl>
	<bibl>. <author>Shiroiwa T, Sung YK, Fukuda T, Lang HC, Bae SC, Tsutani K</author>. <title level="a">International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness?</title> <title level="j">Health Econ</title> <date>2010</date>;<biblScope unit="volume">19</biblScope>:<biblScope unit="page">422e37</biblScope>.</bibl>
	<bibl>. <author>Poole CD, Bannister CA, Andreasen JN, Andersen JS, Currie CJ</author>. <title level="a">Estimation of health-related utility (EQ-5D index) in subjects with seasonal allergic rhino-conjunctivitis to evaluate health gain associated with sublingual grass allergen immunotherapy</title>. <title level="j">Health Qual Life Outcomes</title> <date>2014</date>;<biblScope unit="volume">12</biblScope>:<biblScope unit="page">99</biblScope>.</bibl>
	<bibl>. <author>Mukuria C, Rowen D, Harnan S, Rawdin A, Wong R, Ara R, et al.</author> <title level="a">An updated systematic review of studies mapping (or cross-walking) measures of health-related quality of life to generic preference-based measures to generate util-ity values</title>. <title level="j">Appl Health Econ Health Policy</title> <date>2019</date>;<biblScope unit="volume">17</biblScope>:<biblScope unit="page">295e313</biblScope>.</bibl>
	<bibl>. <author>Tuchiya A, Ikeda S, Ikegami N, Nishmura S, Sakai I, Fukuda T, et al.</author> <title level="a">Esti-mating an EQ-5D population value set: the case of Japan</title>. <title level="j">Health Econ</title> <date>2002</date>;<biblScope unit="volume">11</biblScope>:<biblScope unit="page">341e53</biblScope>.</bibl>
	<bibl>. <author>Monden A, Ogino S</author>. [<title level="a">The evaluation of the utility values for allergic rhinitis using EQ-5D]</title>. [<title level="j">J Jap Soc Immunol Allergy Otorhinolaryngol</title>] <date>2005</date>;<biblScope unit="volume">23</biblScope>:<biblScope unit="page">15e8</biblScope> (<note>in Japanese</note>).</bibl>
	<bibl>. <author>Green W, Kleine-Tebbe J, Klimek L, Hahn-Pedersen J, Andreasen JN, Taylor</author>. <title level="a">Cost-effectiveness of SQR HDM SLIT-tablet in addition to pharmacotherapy for the treatment of house dust mite allergic rhinitis in Germany</title>. <title level="j">Clinicoecon Outcomes Res</title> <date>2017</date>;<biblScope unit="volume">9</biblScope>:<biblScope unit="page">77e84</biblScope>.</bibl>
	<bibl>. <author>Dick K, Briggs A, Ohsfeldt R, Grand TS, Buchs S</author>. <title level="a">A quality-of-life mapping fuction developed from a grass pollen sublingual immunotherapy trial to a tree pollen sublingual immunotherapy trial</title>. <title level="j">J Med Econ</title> <date>2020</date>;<biblScope unit="volume">23</biblScope>:<biblScope unit="page">64e9</biblScope>.</bibl>
	<bibl>. <author>Yu ST, Chang HY, Yao KP, Lin YH, Hurng BS</author>. <title level="a">Validity of EQ-5D in general population of Taiwan: results of the 2009 National Health Interview and Drug Abuse Survey in Taiwan</title>. <title level="j">Qual Life Res</title> <date>2015</date>;<biblScope unit="volume">24</biblScope>:<biblScope unit="page">2541e8</biblScope>.</bibl>
	<bibl>. <author>Caimmi D, Calderon MA, Bousquet M, Demoly P</author>. <title level="a">Allergen immunotherapy outcomes and unmet needs: a critical review</title>. <title level="j">Immunol Allergy Clin North Am</title> <date>2016</date>;<biblScope unit="volume">36</biblScope>:<biblScope unit="page">181e9</biblScope>.</bibl>
	<bibl>. <author>Okubo K, Okano M, Sato N, Tamaki Y, Suzuki H, Uddin A, et al.</author> <title level="a">Add-on oma-lizumab for inadequately controlled severe pollinosis despite standard-of-care: a randomized study</title>. <title level="j">J Allergy Clin Immunol Pract</title> <date>2020</date>;<biblScope unit="volume">8</biblScope>:<biblScope unit="page">3130e40</biblScope>.</bibl>
	<bibl>. <author>Dick K, Briggs A, Brandi H</author>. <title level="a">Application of a mapping function to estimate utilities for ragweed allergen immunotherapy trials</title>. <title level="j">Pharmacoecon Open</title> <date>2020</date>;<biblScope unit="volume">4</biblScope>:<biblScope unit="page">649e55</biblScope>.</bibl>
	<bibl>. <author>Petou S, Rivero-Arias O, Dakin H, Longworth L, Oppe M, Fround R, et al.</author> <title level="a">The MAPS reporting statement for studies mapping onto generic preference-based outcome measures: explanation and elaboration</title>. <title level="j">Pharmacoeconomics</title> <date>2015</date>;<biblScope unit="volume">33</biblScope>: <biblScope unit="page">993e1011</biblScope>.</bibl>
	<bibl>. <author>Okamoto Y, Okubo K, Yonekura S, Hashiguchi K, Goto M, Otsuka T, et al.</author> <title level="a">Efficacy and safety of sublingual immunotherapy for two seasons in pa-tients with Japanese cedar pollinosis</title>. <title level="j">Int Arch Allergy Immunol</title> <date>2015</date>;<biblScope unit="volume">166</biblScope>: <biblScope unit="page">177e88</biblScope>.</bibl>
	<bibl>. <author>Shiroiwa T, Ikeda S, Noto S, Igarashi A, Fukuda T, Saito S, et al.</author> <title level="a">Comparison of value set based on DCE and/or TTO data: Scoring for EQ-5D-5L health states in Japan</title>. <title level="j">Value Health</title> <date>2016</date>;<biblScope unit="volume">19</biblScope>:<biblScope unit="page">648e54</biblScope>.</bibl>
	<bibl>. <author>Osada T, Okano M</author>. <title level="a">Japanese cedar/cypress pollinosis updated: new allergen, cross-reactivity, and treatment</title>. <title level="j">Allergol Int</title> <date>2021</date>;<biblScope unit="volume">70</biblScope>:<biblScope unit="page">281e90</biblScope>.</bibl>
	<bibl>. <author>Kamae I, Thwaites R, Hamada A, Fernandez JL</author>. <title level="a">Health technology assessment in Japan: a work in progress</title>. <title level="j">J Med Econ</title> <date>2020</date>;<biblScope unit="volume">23</biblScope>:<biblScope unit="page">317e22</biblScope>.</bibl>
	<bibl>. <author>Shiroiwa T</author>. <title level="a">Cost-effectiveness evaluation for pricing medicines and devices: a new value-based price adjustment system in Japan</title>. <title level="j">Int J Technol Assess Health Care</title> <date>2020</date>;<biblScope unit="volume">36</biblScope>:<biblScope unit="page">270e6</biblScope>.</bibl>
	<bibl>. <author>Kishikawa R, Koto E</author>. <title level="a">Effect of climate change on allergenic airborne pollen in Japan</title>. <title level="j">Immunol Allergy Clin N Am</title> <date>2021</date>;<biblScope unit="volume">41</biblScope>:<biblScope unit="page">111e25</biblScope>.</bibl>
	<bibl>. <author>Tamayama K, Kondo M, Shono A, Okubo I</author>. <title level="a">Utility weights for allergic rhinitis based on a community survey with a time trade-off technique in Japan</title>. <title level="j">Allergol Int</title> <date>2009</date>;<biblScope unit="volume">58</biblScope>:<biblScope unit="page">201e7</biblScope>.</bibl>
	<bibl>. <author>Canonica GW, Poulsen PB, Vestenbeak U</author>. <title level="a">Cost-effectiveness of Grazax for prevention of grass pollen induced rhinoconjunctivitis in Southern Europe</title>. <title level="j">Respir Med</title> <date>2007</date>;<biblScope unit="volume">101</biblScope>:<biblScope unit="page">1885e94</biblScope>.</bibl>
	<bibl>. <author>Bachert C, Vestenbeak U, Christensen J, Griffiths UK, Poulsen PB</author>. <title level="a">Cost-effec-tiveness of grass allergen tablet (GRAZAX) for the prevention of seasonal allergic rhinoconjunctivitis e a Northern European perspective</title>. <title level="j">Clin Exp Allergy</title> <date>2007</date>;<biblScope unit="volume">37</biblScope>:<biblScope unit="page">772e9</biblScope>.</bibl>
	<bibl>. <author>Penagos M, Durham SR</author>. <title level="a">Duration of allergen immunotherapy for inhalant al-lergy</title>. <title level="j">Curr Opin Allergy Clin Immunol</title> <date>2019</date>;<biblScope unit="volume">19</biblScope>:<biblScope unit="page">594e605</biblScope>.</bibl>
	<bibl>. <author>Yonekura S, Gotoh M, Kaneko S, Maekawa Y, Okubo K, Okamoto Y</author>. <title level="a">Disease-modifying effect of Japanese cedar pollen sublingual immunotherapy tablets</title>. <title level="j">J Allergy Clin Immunol Pract</title> <date>2021</date>;<biblScope unit="volume">9</biblScope>:<biblScope unit="page">4103e16.e14</biblScope>.</bibl>
	<bibl>. <author>Blaiss M, Maloney J, Nolte H, Gawchik S, Yao R, Skoner DP</author>. <title level="a">Efficacy and safety of timothy grass allergen immunotherapy tablets in North American children and adolescents</title>. <title level="j">J Allergy Clin Immunol</title> <date>2011</date>;<biblScope unit="volume">127</biblScope>:<biblScope unit="page">64e71</biblScope>.</bibl>
	<bibl>. <author>Fujii T, Ogino S, Arimoto H, Irifune M, Iwata N, Ookawachi I, et al.</author> [<title level="a">Quality of life in patients with Japanese cedar pollinosis: using the SF-8 health status questionnaire (Japanese version)</title>]. <title level="j">Arerugi</title> <date>2006</date>;<biblScope unit="volume">55</biblScope>:<biblScope unit="page">1288e94</biblScope> (<note>in Japanese</note>).</bibl>
	<bibl>. <author>Gotoh M, Yonekura S, Imai T, Kaneko S, Hirokawa E, Konno A, et al.</author> <title level="a">Long-term efficacy and dose-finding trial of Japanese cedar pollen sublingual immuno-therapy tablet</title>. <title level="j">J Allergy Clin Immunol Pract</title> <date>2019</date>;<biblScope unit="volume">7</biblScope>:<biblScope unit="page">1787e97</biblScope>.</bibl>

		</listBibl>
	</back>
	</text>
</TEI>
